BCL2L1 armored CAR T cells overcome exhaustion and enhance persistence in multiple myeloma

Basic Information

Funding Cycle : 2023-2024
Name : Nizar Bahlis
Type of Award : Translational Research Award
Home Institution : University of Calgary


The specific aims of this proposed study aim to enhance CAR T cell therapy for multiple myeloma by addressing the mechanisms of resistance and improving persistence of CAR T cells armored with BCL-xL. Aim 1 seeks to determine the role of MM cell death ligands in the resistance of BCL-xL armored CARs to activation-induced cell death (AICD), focusing on death receptor-independent mechanisms. Aim 2 aims to define, at transcriptomic, epigenomic, and metabolic levels, the factors driving the metabolic fitness and persistence of BCL-xL armored CARs, exploring pathways beyond death receptors downstream signaling. These studies aim to provide insights into overcoming resistance and improving the efficacy of CAR T cell therapy for multiple myeloma.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events